SecBot SecBot
144 ·Filed Mar 27, 2026

EWTX

Edgewise Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001950047-26-003048
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for actual sales filings (Form 4) in the coming weeks to confirm if and when the shares are sold. Officer-level sales are routine but should be watched for unusual volume or timing relative to company catalysts.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$30.28
T+0 close · Mar 27, 2026 · via day close
Latest settled
+37.68%
T+60 · $41.69
Vs SPY
+21.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $30.28entry
  2. T+1 · 8mo ago +4.03%α +1.14% · $31.50
  3. T+5 · 7mo ago +7.33%α +3.03% · $32.50
  4. T+20 · 7mo ago +2.34%α −10.25% · $30.99
  5. T+60 · 5mo ago +37.68%α +21.19% · $41.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Joanne Donovan, an officer of Edgewise Therapeutics, filed a Form 144 to notify intent to sell up to 71,588 shares of common stock. The shares were acquired through stock option exercises, an employee stock purchase plan, and restricted stock unit vesting.

Key Facts

  • Joanne Donovan, an officer of Edgewise Therapeutics, intends to sell up to 71,588 shares.
  • The shares consist of 50,000 from stock option exercises, 9,623 from an employee stock purchase plan, and 11,965 from restricted stock unit vesting.
  • The filing was submitted on March 27, 2026, with the sales expected to occur over the next three months.
  • No immediate sale has been reported; this is a notice of proposed sale.

Financial Impact

Approximately $2.27 million based on 71,588 shares at $31.70 per share (implied from filing data)

insider ownershippotential share dilutionmarket sentiment

Risk Factors

  • Perception of insider selling could weigh on investor sentiment, especially if sales occur near key company events.
  • If the sales proceed, it may indicate reduced insider confidence, though the shares are from routine compensation vesting.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-003048
Document: 0001950047-26-003048-index.html0001950047-26-003048
Document: 0001950047-26-003048.txt0001950047-26-003048

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 27, 2026